Chutes & Ladders—Yet another exec departs CRISPR
CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the company’s executive team. Bruno had been with CRISPR for six years, serving in several management roles with increasing responsibility before landing the chief operating officer position last May.
